Evaluation of the Effect of a Nutraceutical Supplement on Hair Growth and Hair Quality in Premenopausal and Menopausal Women

1. Participant having signed an Informed Consent Form (ICF);
2. Female participant aged 45 to 60 years, inclusive;
3. Participant with skin type I to IV according to the Fitzpatrick scale;
4. Participant experiencing irregular menstrual cycles and vasomotor symptoms (e.g., hot flashes) for more than 6 months, without having experienced complete amenorrhea for 12 consecutive months OR Participant with a spontaneous amenorrhea lasting 12 months or more, not attributable to any pathological or hormonal cause;
5. Participant reporting self-perceived hair thinning or reduced hair density, with clinical confirmation by a qualified person*;
6. Participant with hair length ≥ 3 cm on the vertex and agreeing to keep this minimum length for the duration of the study;
7. Participant with previously colored hair, willing to maintain regular hair coloring practices consistently during the study period;
8. Participant agreeing to have a shaved zone of 1.8 cm² on scalp area;
9. Participant accepting not to use any product for scalp care other than non-treating shampoo. Hair gel, spray and styling product are authorized except on days of visit to center;
10. Participant accepting not to take any treatment (oral or topical route) that could interfere with hair growth, diameter or hair fall throughout the study period;
11. Participant accepting not to bleach her hair or undergo a permanent waving throughout the study period;
12. Participant willing and able to follow all the study procedures and restrictions and complete the whole study phase;
13. Participant affiliated to a health social security system (according to French Law).

Exclusion Criteria:

1. Male participant;
2. Pregnant or breastfeeding participant;
3. Participant with a BMI ≤ 17 or ≥ 32 kg/cm²;
4. Participant who has undergone a hysterectomy and/or bilateral oophorectomy, or who presents with ovarian insufficiency;
5. Participant presenting a life-threatening endocrine disease, neoplasia or other serious diseases;
6. Participant suffering from chemo-induced alopecia (poisoning, medicines), or resulting from a chronic disease (genetic, endocrine, immunological, deficiencies);
7. Participant having any other concomitant dermatological affection of the scalp (psoriasis, seborrheic dermatitis, eczema, scarring alopecia or autoimmune hair loss, severe androgenetic alopecia, recent acute telogen effluvium);
8. Participant suffering from a recurrent, acute, non-stabilized or evolving disease judged by the investigator able to interfere with the study needs and hair growth;
9. Participant with an history of eating disorder (e.g. anorexia, food allergy) or gastro-intestinal malabsorption such as celiac disease, Crohn's disease, lactose intolerance;
10. Participant with an history of sleeve or bypass;
11. Participant with known or suspected hypersensitivity to any component(s) of the investigational products or to any ingredients of the vehicles (i.e., excipients);
12. Participant having had surgical intervention for capillary correction (e.g., hair transplant) or intending to have recourse to this surgery during the entire study period;
13. Participant that has applied or taken prior to the start of the study (screening) the following treatments and/or procedures:

Participant taking any other medical treatment (topic or per os) likely to interfere on hair growth or hair loss within 6 months prior to the screening visit; 15. Participant following a long period (>30 days) treatment of anti-inflammatory within 4 months prior to the start of the study (screening visit); 16. Participant taking topic cosmetic treatment or per os nutraceutical supplement likely to interfere on hair growth or hair loss during the last 3 months prior to the screening visit; 17. Participant having a topical or oral route treatment of the scalp (anti-seborrheic, anti-dandruff, daily friction) within 2 weeks prior to the screening visit; 18. Participant who has been exposed within one month prior to the screening visit in an intense or excessive manner to sun (natural or artificial) or during the study; 19. Participant having a wig or hair extension; 20. Protected participant as defined in the Articles of the French Public Health Code. Article 1121-7: person deprived of liberty by a judicial or administrative decision, or subject to psychiatric care, or person admitted to a health or social institution for purposes other than the research.

Article 1121-8: adult person subject to a legal protection measure or unable to express his/her consent; 21. Participant unable to communicate or cooperate with the Investigator due to poor mental development, language problems or impaired cerebral function; 22. Participant currently participating in another clinical study or being in an exclusion period of another clinical study; 23. Subject having received 6000 euros indemnities for participation in clinical trials/investigations in the 12 previous months, including participation in the present study (according to French Law).